Search clinical trials for: Mobocertinib

Total 10 results

Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Takeda

Completed

A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys

Renal Impairment | Healthy Volunteers

United States
Takeda

Withdrawn

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Non-Small Cell Lung Cancer (NSCLC)
Millennium Pharmaceuticals, Inc.

Approved for marketing

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Carcinoma, Non-Small-Cell Lung
Takeda

Active, not recruiting

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Japan
Takeda

Active, not recruiting

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, France, Korea, Republic of, Israel, Hong Kong, Australia, Taiwan, United Kingdom, Canada, Turkey, Italy, China, Germany, Russian Federation, Switzerland, Austria, Japan, Denmark, Belgium, Greece, Netherlands, P... and more
Millennium Pharmaceuticals, Inc.

Completed

Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

Australia, Singapore, Netherlands
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

Healthy Volunteers

United States

3

Subscribe